# The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials

## Supplementary Material

**Supplementary Table S1.** Inclusion and exclusion criteria according to PICOS

| | **Inclusion Criteria** | **Exclusion Criteria** |
|---|---|---|
| **Population** | All patients receiving upadacitinib | Patients not receiving upadacitinib |
| **Intervention** | Administration of upadacitinib, alone or in conjunction with background treatment | Other interventions, including other JAK inhibitors |
| **Comparator** | Placebo, or any other intervention | Does not apply |
| **Outcome** | Effect on lipid profile (LDL-C, HDL-C, LDL-C:HDL-C) and/or major adverse cardiovascular events (i.e., stoke, cardiovascular death, myocardial infarction). | Other outcomes, or lack of data regarding specific lipid variables of interest (i.e., LDL-C, HDL-C, LDL-C:HDL-C and major adverse cardiovascular events). |
| **Study Design** | Only randomized control trials | Other study designs |

| **Supplementary Table S2. Reasons for exclusion** | |
|---|---|
| **Study** | **Reasons for exclusion** |
| Silverberg et al., 2021 | No data on lipoproteins, no data on MACE for control group |
| Deodhar et al., 2021 | No data on lipoproteins, no data on MACE for control group |
| Fleischmann et al., 2022 | No data on lipoproteins, no data on MACE for control group |
| Heijde et al., 2022 | No data on lipoproteins, no data on MACE for control group |
| McInnes et al., 2021 | No data on lipoproteins, no data on MACE for control group |
| Blauvelt et al., 2021 | No data on lipoproteins, no data on MACE for control group |
| Mease et al., 2021 | No data on lipoproteins, no data on MACE for control group |
| Kameda et al., 2021 | No data on lipoproteins, no data on MACE for control group |
| Sandborn et al., 2020 | No data on lipoproteins or MACE |
| Vermeire et al., 2021 | No data on lipoproteins or MACE |
| Pavelka et al., 2020 | Sub-analysis of identified trial |
| Yamaoka et al., 2021 | Sub-analysis of identified trial |
| NCT02049138 (BALANCE-EXTEND) | Sub-analysis of identified trial |
| Danese et al., 2021 | Identical to identified trial |